mpt pharma limited
mpt pharma limited Company Information
Company Number
06006092
Next Accounts
Jan 2026
Shareholders
cst holdings (uk) ltd
Group Structure
View All
Industry
Packaging activities
Registered Address
unit 5-7 tintagel way, westgate park industrial estate, walsall, WS9 8ER
Website
cstpharma.co.ukmpt pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MPT PHARMA LIMITED at £263.2k based on a Turnover of £508.7k and 0.52x industry multiple (adjusted for size and gross margin).
mpt pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MPT PHARMA LIMITED at £0 based on an EBITDA of £0 and a 3.19x industry multiple (adjusted for size and gross margin).
mpt pharma limited Estimated Valuation
Pomanda estimates the enterprise value of MPT PHARMA LIMITED at £245 based on Net Assets of £100 and 2.46x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Mpt Pharma Limited Overview
Mpt Pharma Limited is a live company located in walsall, WS9 8ER with a Companies House number of 06006092. It operates in the packaging activities sector, SIC Code 82920. Founded in November 2006, it's largest shareholder is cst holdings (uk) ltd with a 100% stake. Mpt Pharma Limited is a established, small sized company, Pomanda has estimated its turnover at £508.7k with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Mpt Pharma Limited Health Check
Pomanda's financial health check has awarded Mpt Pharma Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 5 areas for improvement. Company Health Check FAQs
1 Strong
1 Regular
5 Weak
Size
annual sales of £508.7k, make it smaller than the average company (£12.9m)
- Mpt Pharma Limited
£12.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 293%, show it is growing at a faster rate (4.3%)
- Mpt Pharma Limited
4.3% - Industry AVG
Production
with a gross margin of 17.2%, this company has a higher cost of product (27.6%)
- Mpt Pharma Limited
27.6% - Industry AVG
Profitability
an operating margin of 0% make it less profitable than the average company (4.6%)
- Mpt Pharma Limited
4.6% - Industry AVG
Employees
with 4 employees, this is below the industry average (42)
4 - Mpt Pharma Limited
42 - Industry AVG
Pay Structure
on an average salary of £38k, the company has an equivalent pay structure (£38k)
- Mpt Pharma Limited
£38k - Industry AVG
Efficiency
resulting in sales per employee of £127.2k, this is less efficient (£263k)
- Mpt Pharma Limited
£263k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Mpt Pharma Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Mpt Pharma Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Mpt Pharma Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Mpt Pharma Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Mpt Pharma Limited
- - Industry AVG
MPT PHARMA LIMITED financials
Mpt Pharma Limited's latest turnover from April 2024 is estimated at £508.7 thousand and the company has net assets of £100. According to their latest financial statements, Mpt Pharma Limited has 4 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | |||||||||||||||
| Tax | |||||||||||||||
| Profit After Tax | |||||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | |||||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | 4 | 5 | 113 | 102 | 94 | ||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 45,903 | 36,604 | 36,178 | 48,237 | 30,722 | 34,246 | 34,040 | 45,386 | 53,123 | 51,964 | |||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 45,903 | 36,604 | 36,178 | 48,237 | 30,722 | 34,246 | 34,040 | 45,386 | 53,123 | 51,964 | |||||
| Stock & work in progress | 662,050 | 637,728 | 656,938 | 624,934 | 402,668 | 206,648 | 178,329 | 121,685 | 109,991 | 83,500 | |||||
| Trade Debtors | 233,829 | 138,481 | 92,814 | 34,051 | 34,379 | 40,623 | |||||||||
| Group Debtors | 100 | 95 | 95 | 2,320 | |||||||||||
| Misc Debtors | 71,401 | 1,861,204 | 1,008,646 | 18,474 | |||||||||||
| Cash | 5 | 5 | 257 | 63 | 175 | 857 | 2,427 | 911 | 100 | 2,368 | 34,224 | 2,298 | 54,689 | ||
| misc current assets | 47,475 | 47,475 | 47,475 | ||||||||||||
| total current assets | 100 | 100 | 100 | 2,577 | 63 | 733,626 | 2,547,264 | 1,715,486 | 691,794 | 636,597 | 345,129 | 273,511 | 189,960 | 146,668 | 178,812 |
| total assets | 100 | 100 | 100 | 2,577 | 63 | 779,529 | 2,583,868 | 1,751,664 | 740,031 | 667,319 | 379,375 | 307,551 | 235,346 | 199,791 | 230,776 |
| Bank overdraft | 34 | 107 | |||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 2,477 | 182,343 | 87,201 | 278,384 | 1,383,415 | 454,211 | 654,184 | 504,009 | 279,853 | 226,313 | 199,930 | 244,136 | |||
| Group/Directors Accounts | 96,927 | 489,113 | |||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 482,354 | 2,348,802 | 270,105 | 281,213 | |||||||||||
| total current liabilities | 2,477 | 279,304 | 1,058,775 | 2,627,186 | 1,653,520 | 735,424 | 654,184 | 504,009 | 279,853 | 226,313 | 199,930 | 244,136 | |||
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 8,722 | 6,955 | 7,206 | 9,647 | 6,144 | 7,315 | 7,315 | 9,584 | 11,131 | 10,889 | |||||
| total long term liabilities | 8,722 | 6,955 | 7,206 | 9,647 | 6,144 | 7,315 | 7,315 | 9,584 | 11,131 | 10,889 | |||||
| total liabilities | 2,477 | 279,304 | 1,067,497 | 2,634,141 | 1,660,726 | 745,071 | 660,328 | 511,324 | 287,168 | 235,897 | 211,061 | 255,025 | |||
| net assets | 100 | 100 | 100 | 100 | -279,241 | -287,968 | -50,273 | 90,938 | -5,040 | 6,991 | -131,949 | 20,383 | -551 | -11,270 | -24,249 |
| total shareholders funds | 100 | 100 | 100 | 100 | -279,241 | -287,968 | -50,273 | 90,938 | -5,040 | 6,991 | -131,949 | 20,383 | -551 | -11,270 | -24,249 |
| Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 15,301 | 12,202 | 12,059 | 9,019 | 9,444 | 11,346 | 14,027 | 15,007 | 9,844 | ||||||
| Amortisation | |||||||||||||||
| Tax | |||||||||||||||
| Stock | -662,050 | 24,322 | -19,210 | 32,004 | 222,266 | 196,020 | 28,319 | 56,644 | 11,694 | 26,491 | 83,500 | ||||
| Debtors | 5 | -2,225 | 2,320 | -71,401 | -1,789,803 | 852,558 | 990,172 | -215,355 | 95,348 | 45,667 | 58,763 | -328 | -6,244 | 40,623 | |
| Creditors | -2,477 | -179,866 | 95,142 | -191,183 | -1,105,031 | 929,204 | -199,973 | 150,175 | 224,156 | 53,540 | 26,383 | -44,206 | 244,136 | ||
| Accruals and Deferred Income | -482,354 | -1,866,448 | 2,078,697 | -11,108 | 281,213 | ||||||||||
| Deferred Taxes & Provisions | -8,722 | 1,767 | -251 | -2,441 | 3,503 | -1,171 | -2,269 | -1,547 | 242 | 10,889 | |||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -96,927 | -392,186 | 489,113 | ||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | |||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | -5 | -252 | 194 | -112 | -682 | -1,570 | 1,516 | 811 | 100 | -2,368 | -31,856 | 31,926 | -52,391 | 54,689 | |
| overdraft | -34 | -73 | 107 | ||||||||||||
| change in cash | -5 | -252 | 228 | -39 | -789 | -1,570 | 1,516 | 811 | 100 | -2,368 | -31,856 | 31,926 | -52,391 | 54,689 |
mpt pharma limited Credit Report and Business Information
Mpt Pharma Limited Competitor Analysis
Perform a competitor analysis for mpt pharma limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other small companies, companies in WS9 area or any other competitors across 12 key performance metrics.
mpt pharma limited Ownership
MPT PHARMA LIMITED group structure
Mpt Pharma Limited has no subsidiary companies.
Ultimate parent company
2 parents
MPT PHARMA LIMITED
06006092
mpt pharma limited directors
Mpt Pharma Limited currently has 4 directors. The longest serving directors include Mr Jason Yates (Aug 2018) and Mr Carl Falzon (Aug 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Jason Yates | England | 51 years | Aug 2018 | - | Director |
| Mr Carl Falzon | England | 47 years | Aug 2018 | - | Director |
| Mrs Caroline Poynter | United Kingdom | 60 years | Aug 2018 | - | Director |
| Mr Ian Pritchard | 55 years | Aug 2019 | - | Director |
P&L
April 2024turnover
508.7k
0%
operating profit
-0.1
0%
gross margin
17.2%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
April 2024net assets
100
0%
total assets
100
0%
cash
0
-1%
net assets
Total assets minus all liabilities
mpt pharma limited company details
company number
06006092
Type
Private limited with Share Capital
industry
82920 - Packaging activities
incorporation date
November 2006
age
19
incorporated
UK
ultimate parent company
accounts
Dormant
last accounts submitted
April 2024
previous names
N/A
accountant
-
auditor
-
address
unit 5-7 tintagel way, westgate park industrial estate, walsall, WS9 8ER
Bank
-
Legal Advisor
-
mpt pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 4 charges/mortgages relating to mpt pharma limited. Currently there are 4 open charges and 0 have been satisfied in the past.
mpt pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MPT PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
mpt pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
